TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12644982

Group type: EXPERIMENTAL
Intervention: ZD1839 250 mg/day
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: ZD1839 500 mg/day
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: ZD1839 250 mg/day (IDEAL-2)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: ZD1839 500 mg/day (IDEAL-2)
Number of subjects: 431
Study: 9660028

Group type: EXPERIMENTAL
Intervention: Vaccinia melanoma oncolysate (VMO) - 1 U containing 2 mg of total protein derived from 5 x 10(6) melanoma cells and 10(5.6) 50% tissue culture infectious dose of vaccinia virus, administered once a week for 13 weeks and then once every 2 weeks for a total of 12 months.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control (V) - 1 U containing 10(5.4) 50% tissue culture infectious dose of vaccinia virus, administered once a week for 13 weeks and then once every 2 weeks for a total of 12 months.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Vaccinia melanoma oncolysate (VMO) - in a retrospective subset analysis of male patients aged 44-57 years with one to five positive nodes (n = 20).
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control (V) - in a retrospective subset analysis of male patients aged 44-57 years with one to five positive nodes (n = 18).
Number of subjects: 250
Study: 7752665

Group type: EXPERIMENTAL
Intervention: Dynamic aerobic training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise programs
Number of subjects: 0
Study: 2676535

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 59

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both Sotalol and Amiodarone
Number of subjects: 59
Study: 820425

Group type: EXPERIMENTAL
Intervention: Bipedal lymphography and exploratory laparotomy with selective node biopsy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: T1 and T2 tumors (Stage B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: T3 tumors (Stage C)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Poorly differentiated tumors
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Well‐differentiated tumors
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Exploratory laparotomy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients with lymphatic metastases
Number of subjects: 50
Study: 29247405

Group type: EXPERIMENTAL
Intervention: Demoralization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both conditions (depression and demoralization)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No affective conditions
Number of subjects: 0
Study: 28033031

Group type: EXPERIMENTAL
Intervention: Intervention condition with staff training
Number of subjects: 379

Group type: COMPARATOR
Intervention: Control condition (not explicitly detailed)
Number of subjects: 379
Study: 25795408

Group type: EXPERIMENTAL
Intervention: Linsitinib (150 mg oral, twice daily)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Linsitinib
Number of subjects: 139
Study: 24060561

Group type: COMPARATOR
Intervention: Reference formulation (4 tablets of 100 mg imatinib)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Test formulation (1 tablet of 400 mg imatinib)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 30
Study: 20199722

Group type: EXPERIMENTAL
Intervention: Angiography combined with transthoracic echocardiography (TEE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional transcatheter occlusion
Number of subjects: 40
Study: 18986387

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m², days 1, 4, 8, and 11 for eight 3-week cycles, then days 1, 8, 15, and 22 for three 5-week cycles)
Number of subjects: 598

Group type: COMPARATOR
Intervention: Dexamethasone (40 mg/d, days 1-4, 9-12, and 17-20 for four 5-week cycles, then days 1-4 only for five 4-week cycles)
Number of subjects: 598
Study: 16511418

Group type: EXPERIMENTAL
Intervention: Four-drug regimen
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Three-drug regimen
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Protease inhibitor-containing ART
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (15 patients who declined therapy)
Number of subjects: 105
Study: 12756389

Group type: EXPERIMENTAL
Intervention: Parents' attitudes towards trial participation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Parental factors influencing trial participation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Child factors influencing trial participation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Trial factors influencing trial participation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Doctor factors influencing trial participation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Recommendations for increasing participation
Number of subjects: 33
Study: 11149995

Group type: EXPERIMENTAL
Intervention: Terfenadine premedication
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo premedication
Number of subjects: 47
Study: 9562219

Group type: EXPERIMENTAL
Intervention: Nasal dilatator
Number of subjects: 10
Study: 7829945

Group type: EXPERIMENTAL
Intervention: Prednisolone tablets (1 mg/kg body wt/day up to 70 mg) for six successive days, then gradually reduced over the next four days
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no prednisolone)
Number of subjects: 160
Study: 3341273

Group type: EXPERIMENTAL
Intervention: Adriamycin (90 mg/m2 given over 2 days, once a month for 5 months)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control (no adjuvant chemotherapy)
Number of subjects: 119
Study: 1299795

Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Breakfast
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no caffeine or breakfast)
Number of subjects: 48
Study: 330893

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inert aerosol placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol after placebo
Number of subjects: 30
Study: 30334166

Group type: EXPERIMENTAL
Intervention: Physical surgical trainer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Virtual trainer
Number of subjects: 18

Group type: COMPARATOR
Intervention: Untrained subjects
Number of subjects: 18
Study: 28134056

Group type: EXPERIMENTAL
Intervention: Family-led caregiver delivered rehabilitation program after stroke
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 26012577

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 150
Study: 25675798

Group type: EXPERIMENTAL
Intervention: Tubal ectopic pregnancy (EP) group
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (healthy intrauterine gestations)
Number of subjects: 157
Study: 22479375

Group type: EXPERIMENTAL
Intervention: Educational material (photo-novel) tailored to increase knowledge about SPC screening
Number of subjects: 326

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 326

Group type: COMPARATOR
Intervention: Both intervention and control groups
Number of subjects: 326
Study: 19104452

Group type: EXPERIMENTAL
Intervention: Protein S-100B assessment
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Lactate dehydrogenase (LDH) assessment
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: S-100B assessment
Number of subjects: 97
Study: 17542353

Group type: EXPERIMENTAL
Intervention: Lecital 40 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cipramil 40 mg
Number of subjects: 24
Study: 15601422

Group type: EXPERIMENTAL
Intervention: celecoxib
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: rofecoxib
Number of subjects: 66

Group type: COMPARATOR
Intervention: cisapride (positive control)
Number of subjects: 66

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 66
Study: 11384657

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethylstarch
Number of subjects: 16

Group type: COMPARATOR
Intervention: human albumin
Number of subjects: 16
Study: 9709042

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (4 mg)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone (0.6 mg/kg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 11271219

Group type: COMPARATOR
Intervention: OKT3 (n=15)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulins (ALG) (n=23)
Number of subjects: 38

Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: ALG
Number of subjects: 38
Study: 2597714

Group type: EXPERIMENTAL
Intervention: Neutrophil-change group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lymphocyte-change group
Number of subjects: 30
Study: 5800368

Group type: EXPERIMENTAL
Intervention: Fructose infusion
Number of subjects: 19
Study: 31894615

Group type: EXPERIMENTAL
Intervention: Youth with ID
Number of subjects: 81510

Group type: COMPARATOR
Intervention: Youth without ID
Number of subjects: 81510
Study: 31424712

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 2058

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2058
Study: 28282703

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 80

Group type: COMPARATOR
Intervention: Water spray (placebo)
Number of subjects: 80
Study: 25923479

Group type: EXPERIMENTAL
Intervention: Whey protein (4 x 10 gram aliquots) during unilateral resistance training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (maltodextrin) during unilateral resistance training
Number of subjects: 12
Study: 23833917

Group type: EXPERIMENTAL
Intervention: Test dentifrice containing 0.454% w/w stannous fluoride
Number of subjects: 137

Group type: COMPARATOR
Intervention: Marketed control dentifrice containing 0.76% w/w sodium monofluorophosphate (Colgate Cavity Protection)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Marketed comparator dentifrice containing 0.454% w/w stannous fluoride (Crest Pro‐Health ‐ Clean Mint)
Number of subjects: 137
Study: 21618201

Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (125 mg SC on days 1 and 8, then weekly; plus IV loading dose ∼10 mg/kg on day 1)
Number of subjects: 1457

Group type: COMPARATOR
Intervention: Intravenous abatacept (∼10 mg/kg on days 1, 15, and 29, then every 4 weeks)
Number of subjects: 1457

Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept
Number of subjects: 1457

Group type: COMPARATOR
Intervention: Intravenous abatacept
Number of subjects: 1457
Study: 19813273

Group type: EXPERIMENTAL
Intervention: Active PSA-screening every second year (attendees)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Nonattendees (not participating in screening)
Number of subjects: 10000
Study: 16961169

Group type: EXPERIMENTAL
Intervention: Gabapentin preparation 1 (400 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Gabapentin preparation 2 (400 mg)
Number of subjects: 26
Study: 15569517

Group type: EXPERIMENTAL
Intervention: Acute dipterex poisoning (ADPP)
Number of subjects: 82
Study: 10876451

Group type: EXPERIMENTAL
Intervention: 2.5% lidocaine‐‐2.5% prilocaine cream (LPC)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Dichlorotetrafluoroethane spray (DCTF)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Normal saline with 0.9% benzyl alcohol (BA)
Number of subjects: 280
Study: 9490458

Group type: EXPERIMENTAL
Intervention: Proposals for harmonizing assessment of outcomes and predictors in rehabilitation studies.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concept for pre-post and follow-up measurement in rehabilitation studies.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Descriptions of self-assessment instruments for cross-study comparisons.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Procedure to assess direct and indirect costs of rehabilitation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provisions for ensuring representativeness of women in intervention studies.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Establishment of a coordination committee for harmonization.
Number of subjects: 0
Study: 1396258

Group type: EXPERIMENTAL
Intervention: Amniotomy with oxytocin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous professional support during labour
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent presence of a member of staff
Number of subjects: 0
Study: 3926510

Group type: EXPERIMENTAL
Intervention: High sodium intake (300 mmol)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low sodium intake (50-100 mmol)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control period (normal sodium intake)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg per kg body weight) administered intravenously
Number of subjects: 25
Study: 30877090

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily
Number of subjects: 2155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2155
Study: 30035581

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Assessment-only treatment as usual (TAU)
Number of subjects: 180
Study: 28376282

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Prolonged exposure (PE)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Relaxation therapy (RT)
Number of subjects: 110
Study: 25750322

Group type: EXPERIMENTAL
Intervention: P53-positive tumors (nuclear expression in >10% of cells or absent pattern)
Number of subjects: 884

Group type: COMPARATOR
Intervention: P53-negative tumors (nuclear expression in <10% of cells)
Number of subjects: 884
Study: 23855131

Group type: EXPERIMENTAL
Intervention: Non-sodium restricted diet with diuretics (sodium chloride 6500-8000 mg daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sodium restricted diet with diuretics (sodium chloride 5000 mg daily)
Number of subjects: 80
Study: 20525111

Group type: EXPERIMENTAL
Intervention: HeRO Vascular Access Device
Number of subjects: 1
Study: 18563956

Group type: EXPERIMENTAL
Intervention: Intramuscular aripiprazole 5 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral aripiprazole 5 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous aripiprazole 2 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intramuscular aripiprazole (doses from 1 mg to 45 mg)
Number of subjects: 50
Study: 16369989

Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT‐11) administered at 20 mg/m2/day for 5 days a week for 2 consecutive weeks, repeated every 4 weeks for at least 2 courses.
Number of subjects: 32
Study: 14717271

Group type: EXPERIMENTAL
Intervention: FluMist (intranasal flu vaccine)
Number of subjects: 0
Study: 11326930

Group type: EXPERIMENTAL
Intervention: Mifepristone 75 mg orally for 2 days (total 150 mg) + misoprostol 0.6 mg orally every 3-4 hours for 3 times
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Mifepristone 100 mg orally for 2 days (total 200 mg) + misoprostol 0.6 mg orally every 3-4 hours for 3 times
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Mifepristone 75 mg orally for 2 days (total 150 mg) + misoprostol vaginally every 12 hours for 3 times
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Mifepristone 100 mg orally for 2 days (total 200 mg) + misoprostol vaginally every 12 hours for 3 times
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal route
Number of subjects: 2007
Study: 8735776

Group type: EXPERIMENTAL
Intervention: Iron solution with ascorbic acid added to domestic drinking water for 4 months
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 88
Study: 1750592

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg night sedation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg night sedation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Placebo night sedation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam 5 mg
Number of subjects: 6
Study: 6117662

Group type: EXPERIMENTAL
Intervention: Oral bethanechol chloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31135731

Group type: EXPERIMENTAL
Intervention: Tight control (glucose measurements hourly and treatment for maternal glucose levels lower than 60 mg/dL or greater than 100 mg/dL)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Liberalized control (glucose measurements every 4 hours and treatment for maternal glucose levels lower than 60 mg/dL or greater than 120 mg/dL)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Tight control
Number of subjects: 76

Group type: COMPARATOR
Intervention: Liberalized control
Number of subjects: 76
Study: 28543940

Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg monthly)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Teriparatide (20 μg daily)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 25452626

Group type: EXPERIMENTAL
Intervention: Women-only CR
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Mixed-sex CR
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Home-based CR
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Overall satisfaction across all models
Number of subjects: 169
Study: 22841526

Group type: EXPERIMENTAL
Intervention: 4 mL/kg of 7.2% NaCl/hydroxyethyl starch (HSH group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 0.9% NaCl (control group)
Number of subjects: 26
Study: 21719441

Group type: EXPERIMENTAL
Intervention: Intensive care for children with leukaemia who survived SAEV
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Children requiring haemodialysis
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Children requiring cardiac resuscitation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Patients with more than three identified risk factors
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: ALL and AML patients with SAEV
Number of subjects: 88
Study: 19219022

Group type: EXPERIMENTAL
Intervention: tat‐vpr‐specific anti‐HIV ribozyme (OZ1)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 16421186

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12709693

Group type: EXPERIMENTAL
Intervention: Conscious analgesia/sedation with remifentanil (0.20 to 0.25 microg/kg/min) and propofol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA) with fentanyl (2 microg/kg), midazolam (0.05 mg/kg), and propofol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Conscious analgesia/sedation with remifentanil and propofol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 100
Study: 10862445

Group type: EXPERIMENTAL
Intervention: Meropenem (2 g daily)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (2 g daily)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 53
Study: 1486118

Group type: EXPERIMENTAL
Intervention: Thallium-201 reinjection at rest after conventional stress-redistribution imaging (88 patients)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Thallium-201 reinjection at rest on a separate day (55 patients)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Conventional stress-redistribution imaging
Number of subjects: 143
Study: 3030864

Group type: EXPERIMENTAL
Intervention: Combination measles, mumps, rubella, varicella vaccine (MMRV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard measles, mumps, rubella vaccine and subsequent varicella vaccine (MMR + V)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MMRV
Number of subjects: 20

Group type: COMPARATOR
Intervention: MMR + V
Number of subjects: 20
Study: 31446581

Group type: EXPERIMENTAL
Intervention: 10.6-μm infrared laser moxibustion
Number of subjects: 143

Group type: COMPARATOR
Intervention: Traditional moxibustion
Number of subjects: 143
Study: 30541224

Group type: EXPERIMENTAL
Intervention: 12-hour training program with the theme of expressing empathy to patients using a role-playing technique
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 77
Study: 27705267

Group type: EXPERIMENTAL
Intervention: Daratumumab + Lenalidomide + Dexamethasone
Number of subjects: 569

Group type: COMPARATOR
Intervention: Control (Lenalidomide + Dexamethasone)
Number of subjects: 569
Study: 24434732

Group type: EXPERIMENTAL
Intervention: SCION-PAIN program (multimodular structured intervention)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: SCION-PAIN program
Number of subjects: 263

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 263
Study: 22580235

Group type: EXPERIMENTAL
Intervention: rhDNAse 2.5 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: rhDNAse 5.0 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: rhDNAse 7.5 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: rhDNAse (all doses)
Number of subjects: 50
Study: 20074264

Group type: EXPERIMENTAL
Intervention: Subtotal abdominal hysterectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Total abdominal hysterectomy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 200
Study: 17462643

Group type: EXPERIMENTAL
Intervention: 500 IU hCG every other day for 3 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: T administration alone
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: hCG (0, 125 IU, 250 IU, or 500 IU every other day) for 3 weeks
Number of subjects: 29
Study: 16179085

Group type: EXPERIMENTAL
Intervention: CQ-MB (25 mg/kg CQ and 12 mg/kg MB over three days)
Number of subjects: 226

Group type: COMPARATOR
Intervention: CQ (25 mg/kg over three days)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: CQ-MB and CQ
Number of subjects: 226